RECORD // Company

Incyte Corp

Formerly: INCYTE INC; INCYTE GENOMICS INC; INCYTE PHARMACEUTICALS INC

Built 2026-11-21T11:35:40Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
  • INCYTE CORPORATION · legal entity in this company's GLEIF ownership tree (LEI 549300Z4WN6JVZ3T4680)
SEC EDGAR (1)
  • INCYTE CORP · the SEC registrant record of this company
Matched by name only, not merged (17)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Incyte Corporation · Breach states · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte Corporation · Breach states · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte Corporation (The Lash Group, LLC) · Breach states · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte Corporation · Ca breach · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte Corporation · Ca business · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte Corporation · Corp enforcement · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte Corporation · Corp enforcement · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORPORATION · Ct business · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte Corporation · Ctgov · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Incyte, Inc · Ctgov · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORPORATION · East licences · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORPORATION · East licences · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORPORATION · East licences · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORP. · Epa echo · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORPORATION · Epa echo · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORPORATION · Epa echo · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INCYTE CORPORATION · USAspending · same registered legal name as 'INCYTE CORP' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0000879169-26-000066

ItemValuePeriodFormFiledAccessionReport
Revenue$1,557,204,0003 months ended 2026-09-3010-Q2026-10-290000879169-26-0000662026-11-21 11:35 UTCReport an error
Net income (loss)$-784,803,0003 months ended 2026-09-3010-Q2026-10-290000879169-26-0000662026-11-21 11:35 UTCReport an error
Interest expense$605,0003 months ended 2026-09-3010-Q2026-10-290000879169-26-0000662026-11-21 11:35 UTCReport an error
Cash and cash equivalents$3,275,881,000at 2026-09-3010-Q2026-10-290000879169-26-0000662026-11-21 11:35 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000879169
Ticker
INCY
EIN
943136539
UEI
ZTM9U2G5VTK8
CUSIP
45337C102
Record ID
sx:sec:0000879169

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

38 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-18SEC EDGAR company profile2026-11-21 11:35 UTCReport an error
SIC industry8731 Services-Commercial Physical & Biological Research2026-11-18SEC EDGAR company profile2026-11-21 11:35 UTCReport an error
State of incorporationDE2026-11-18SEC EDGAR company profile2026-11-21 11:35 UTCReport an error
Fiscal year end (MMDD)12312026-11-18SEC EDGAR company profile2026-11-21 11:35 UTCReport an error
Business address1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 198032026-11-18SEC EDGAR company profile2026-11-21 11:35 UTCReport an error
ExchangesNasdaq2026-11-18SEC EDGAR company profile2026-11-21 11:35 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$5,141,242,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:35 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$1,286,650,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:35 UTCReport an error
Total assets (at 2025-12-31)$6,957,973,0002025-12-3110-K, XBRL Assets2026-11-21 11:35 UTCReport an error
Stockholders' equity (at 2025-12-31)$5,167,478,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:35 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$3,097,817,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:35 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$1,413,498,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:35 UTCReport an error
Operating lease liabilities (at 2025-12-31)$20,205,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:35 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-13)Incyte Corporation (the “Company”) has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the Company’s selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer, which had been expected to begin in the fourth quarter of 2026. The Company’s determination was based on the prioritization of its clinical development portfolio and was not based on any safety or efficacy findings from the INCB123667 clinical program. The Company does not expect this determination to affect its financial guidance or its previously disclosed long-term outlook. 22026-11-13SEC EDGAR 8-K 0000879169-26-000068 (text as filed, excerpt)2026-11-21 11:35 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-29)On October 29, 2026 , Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1.2026-10-29SEC EDGAR 8-K 0000879169-26-000063 (text as filed, excerpt)2026-11-21 11:35 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-31)Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation. Under the agreement, the Company will enable state Medicaid programs to access Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations. Additionally, the Company expects that it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. The Company does not expect the agreement to affect its 2026 financial guidance or…2026-08-31SEC EDGAR 8-K 0000879169-26-000058 (text as filed, excerpt)2026-11-21 11:35 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-07-28)On July 28, 2026 , Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1.2026-07-28SEC EDGAR 8-K 0000879169-26-000053 (text as filed, excerpt)2026-11-21 11:35 UTCReport an error
Employer name (as filed)Incyte Corporation2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:35 UTCReport an error
Certified LCAs192026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:35 UTCReport an error
Certified LCAs later withdrawn22026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:35 UTCReport an error
Total worker positions on certified LCAs192026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:35 UTCReport an error
Top job titles (title, LCA count)Senior Principal Biostatistician (5); Senior Research Investigator, Chemistry (2); Biostatistical Programmer (2); Sr. Clinical Database Programmer (1); Principal Biostatistician (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:35 UTCReport an error
Wage offered, annualized (n, min, median, max)median $150,000 (range $113,776-$224,786, 19 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:35 UTCReport an error
Worksite statesDE; PA2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:35 UTCReport an error
Plan (pension, plan no. 001)INCYTE CORPORATION 401(K) PLAN: 2,470 participants, assets $611,724,8172025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:35 UTCReport an error
Plan (welfare, plan no. 501)INCYTE CORPORATION GROUP BENEFIT PLAN: 1,991 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:35 UTCReport an error
Largest institutional holder #1 (13F as filed): BAKER BROS. ADVISORS LP$3,487,217,7292026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$2,044,188,9072026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #3 (13F as filed): Dodge & Cox$1,355,482,4752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$1,249,713,4012026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #5 (13F as filed): STATE STREET CORP$1,102,124,0092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$883,198,0762026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #7 (13F as filed): AQR CAPITAL MANAGEMENT LLC$603,177,3472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$536,515,8602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #9 (13F as filed): Invesco Ltd.$462,561,0602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Largest institutional holder #10 (13F as filed): WELLINGTON MANAGEMENT GROUP LLP$405,321,0592026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:35 UTCReport an error
Federal award transactions, fiscal year 2026 (this one registration only)$02026-09-30USAspending recipient profile2026-11-21 11:35 UTCReport an error
Number of federal award transactions, fiscal year 2026 (this one registration only)122026-09-30USAspending recipient profile2026-11-21 11:35 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.